S. D. Jong

Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis

E. D. de Vries, A. Crijns, S. de Jong, 2009, British Journal of Cancer.

Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies

Jacqueline A. Hall, Robert Brown, H. Hollema, 2006, British Journal of Cancer.

Molecular prognostic markers in ovarian cancer: toward patient‐tailored therapy

E. D. de Vries, S. de Jong, A. Crijns, 2006, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study.

H. Boezen, H. Hollema, A. V. D. Van Der Zee, 2005, Gynecologic oncology.

Robust and independent metabolic transcriptional components in 34,494 patient-derived samples and cell lines: a resource for translational cancer research

R. Fehrmann, S. de Jong, M. Walvoort, 2020, bioRxiv.

Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.

H. Hollema, A. V. D. Van Der Zee, S. de Jong, 2014, Gynecologic oncology.

Biobanking of patient and patient-derived xenograft ovarian tumour tissue : efficient preservation with low and high fetal calf serum based methods Chapter 4

A. Zee, G. Meersma, H. Klip, 2017 .

Novel targets and clinically relevant models for ovarian cancer

G. Wisman, N. Alkema, S. D. Jong, 2015 .

Identification of genes and pathways associated with cytotoxic T lymphocyte infiltration of serous ovarian cancer

H. Boezen, H. Hollema, A. V. D. Van Der Zee, 2010, British Journal of Cancer.

Telomerase activity as a biomarker for (pre)neoplastic cervical disease in scrapings and frozen sections from patients with abnormal cervical smear.

H. Hollema, A. V. D. Van Der Zee, E. D. de Vries, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

IGF system targeted therapy: Therapeutic opportunities for ovarian cancer.

R. Meijering, S. de Jong, A. Reyners, 2017, Cancer treatment reviews.

Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus

E. D. de Vries, M. Bijl, M. N. Lub-de Hooge, 2004, Annals of the rheumatic diseases.